Loading...
Loading...
SCYX| Name | Value |
|---|---|
| Revenues | 5.8M |
| Cost of Revenue | 14.8M |
| Gross Profit | -9.0M |
| Operating Expense | 14.0M |
| Operating I/L | -23.1M |
| Other Income/Expense | 3.6M |
| Interest Income | 1.4M |
| Pretax | -19.4M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -19.6M |
SCYNEXIS, Inc. is a biotechnology company focused on developing products for the treatment of fungal infections in the United States. Its flagship product, BREXAFEMME (ibrexafungerp tablets), is designed for the treatment of vulvovaginal candidiasis (VVC). The company's lead product candidate, Ibrexafungerp, is being developed as an oral and intravenous drug for various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. SCYNEXIS, Inc. also has research collaborations with several pharmaceutical companies to develop and commercialize rights for ibrexafungerp.
